Zimmer Biomet
Makes joint-replacement implants and robotic systems for orthopedic surgery.
Something off on this page? Send us feedback.
Profile
Sells knee and hip replacement systems alongside sports-medicine, trauma, foot-and-ankle, and other orthopedic products, earning revenue through direct hospital and surgery-center accounts and distributors. Its implant franchises are paired with ROSA robotics and the ZBEdge digital platform, while the Americas remain its largest region.
Designs and manufactures knee and hip replacement systems, sports-medicine and biologic products, trauma and extremity implants, foot-and-ankle devices, craniomaxillofacial and thoracic products, bone cement, and surgical tools. The ZBEdge platform connects ROSA robotics and other digital technologies with implant workflows and data gathered before, during, and after surgery.
Pairs broad reconstructive implant franchises with the instruments, clinical training, consigned inventory, and technical sales support needed around surgical procedures. Hospitals and ambulatory surgery centers buy directly or through distributors across the Americas, EMEA, and Asia Pacific, with the Americas the largest region. Demand and pricing depend on procedure volumes, reimbursement and healthcare cost controls, while product launches require regulatory clearance and reliable component supply.
Company facts
Categories
Key statistics
Year to date +12.1% · Average volume (30d) 2.2M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Reiterate | Hold | $83 | $100 | |
| Aug 6, 2026 | Truist Financial | Target | $92 | $106 | ||
| Aug 6, 2026 | Robert W. Baird | Target | $92 | $104 | ||
| Aug 6, 2026 | UBS | Reiterate | Buy | $115 | $120 | |
| Aug 6, 2026 | Bernstein | Reiterate | Market Perform | $99 | $93 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $2.01 | $2.07 | +3.0% | $2.13B | $2.18B | +2.0% | +2.45% |
| Apr 28, 2026Q1 FY26 | $1.86 | $2.09 | +12.4% | $2.07B | $2.09B | +0.8% | −3.30% |
| Feb 10, 2026Q4 FY25 | $2.38 | $2.42 | +1.7% | $2.22B | $2.24B | +0.9% | +4.61% |
| Nov 5, 2025Q3 FY25 | $1.87 | $1.90 | +1.6% | $2.01B | $2.00B | −0.5% | +1.10% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.91B | $2.08B | $2.00B | $2.24B | $2.09B | $2.18B | |
| Gross profit | $1.36B | $1.49B | $1.44B | $1.45B | $1.51B | $1.54B | |
| Operating income | $292.3M | $300.0M | $351.3M | $287.8M | $373.2M | $326.1M | |
| Net income | $182.0M | $152.8M | $230.9M | $139.5M | $238.1M | $198.3M | |
| Diluted EPS | $0.91 | $0.77 | $1.16 | $0.70 | $1.22 | $1.03 | |
| Gross margin | 71.2% | 71.5% | 72.1% | 64.7% | 72.4% | 70.8% | |
| Operating margin | 15.3% | 14.4% | 17.6% | 12.8% | 17.9% | 15.0% |
Fiscal years (4-quarter sums)FY21 $7.09B · FY22 $6.94B · FY23 $7.39B · FY24 $7.68B · FY25 $8.23B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $410.0M · Total debt $7.48B · Total assets $22.80B · Shareholders' equity $12.62B
Dividends
Raised for 13 straight years — most recently to $0.24 from $0.233 split-adjusted in Mar 2022. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 25, 2026 | Jun 25 | Jul 31 | $0.24 | |
| Mar 31, 2026 | Mar 31 | Apr 30 | $0.24 | |
| Dec 30, 2025 | Dec 30 | Jan 30 | $0.24 | |
| Sep 30, 2025 | Sep 30 | Oct 31 | $0.24 | |
| Jun 26, 2025 | Jun 26 | Jul 31 | $0.24 | |
| Mar 31, 2025 | Mar 31 | Apr 30 | $0.24 | |
| Dec 30, 2024 | Dec 30 | Jan 31 | $0.24 | |
| Sep 30, 2024 | Sep 30 | Oct 31 | $0.24 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 193.46M · Float 193.11M · 99.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Dodge & Cox | 24.12M | 12.47% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 15.61M | 8.07% | 13F | Aug 7, 2026 |
| Harris Associates L P | 12.74M | 6.58% | 13F | Aug 14, 2026 |
| Vanguard Capital Management LLC | 12.63M | 6.53% | 13F | Aug 13, 2026 |
| Capital International Investors | 12.18M | 6.30% | 13F | Aug 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 29, 2026 | Sang Yi | officer: Group President, Asia Pacific | −5,000 | $82.64 |
| Mar 12, 2026 | Lori Winkler | officer: SVP and CHRO | −2,650 | $94.66 |
| Feb 12, 2026 | Sang Yi | officer: Group President, Asia Pacific | −1,000 | $96.49 |
| Sep 11, 2025 | Sang Yi | officer: Group President, Asia Pacific | −1,200 | $103.59 |
| Sep 8, 2025 | Lori Winkler | officer: SVP and CHRO | −1,500 | $104.15 |
Peers
- Stryker
Largest direct rival in knees, hips, trauma, S.E.T., and Mako robotics.
- Johnson & Johnson
Broad orthopedic rival via DePuy Synthes — knees, hips, trauma, robotics, CMF.
- Smith & Nephew (ADR)
Global #4 orthopedics; CORI robotics rivals ROSA in knees, hips, sports med.
- Enovis
DJO-heritage rival in extremities, foot & ankle, shoulder, and knee bracing.
- Globus Medical
Post-NuVasive spine leader expanding into trauma and robotic knee vs ZBH S.E.T.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Zimmer Biomet | $100.91 | −0.00% | $19.52B | 24.6 | 11.5 | 2.3 | +4.8% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Smith & Nephew (ADR) | $28.72 | −0.93% | $12.17B | 19.2 | — | 1.9 | +3.7% |
| Enovis | $24.90 | +0.08% | $1.43B | — | 6.6 | 0.6 | +3.2% |
| Globus Medical | $85.02 | +2.47% | $11.19B | 21.3 | 16.2 | 3.6 | +5.9% |
| Median | 26.2 | 18.4 | 3.6 | +5.9% |